Biohaven Pharmaceutical Holding Co Ltd. CEO Vlad Coric's 2019 pay slips 14% to $6.8M

Biohaven Pharmaceutical Holding Co Ltd. reports 2019 executive compensation

By ExecPay News

Published: March 20, 2020

Biohaven Pharmaceutical Holding Co Ltd. reported fiscal year 2019 executive compensation information on March 20, 2020.

In 2019, five executives at Biohaven Pharmaceutical Holding Co Ltd. received on average a compensation package of $4M, a 11% increase compared to previous year.

Average pay of disclosed executives at Biohaven Pharmaceutical Holding Co Ltd.

Vlad Coric, Chief Executive Officer, received $6.8M in total, which decreased by 14% compared to 2018. 46% of Coric's compensation, or $3.1M, was in option awards. Coric also received $581K in bonus, $550K in salary, $2.5M in stock awards, as well as $13K in other compensation.

For fiscal year 2019, the median employee pay was $165,840 at Biohaven Pharmaceutical Holding Co Ltd.. Therefore, the ratio of Vlad Coric's pay to the median employee pay was 41 to one.

William Jones, Jr, Chief Commercial Officer of Migraine & Common Diseases, received a compensation package of $5.6M. 65% of the compensation package, or $3.6M, was in option awards.

Kimberly Gentile, Senior Vice President, Clinical Operations, earned $2.7M in 2019, a 4% decrease compared to previous year.

James Engelhart, Chief Financial Officer, received $2.6M in 2019, which decreases by 20% compared to 2018.

Elyse Stock, Chief Medical Officer, earned $2.5M in 2019.